Pathophysiology of anthracycline‐ and radiation‐associated cardiomyopathies: Implications for screening and prevention
Pediatric Blood & Cancer2005Vol. 44(7), pp. 600–606
Citations Over TimeTop 10% of 2005 papers
Abstract
Great progress has been made in treating childhood cancers over the past 40 years. Along with second malignancies, a major complication of anti-cancer therapies is adverse cardiovascular effects, especially cardiomyopathy and coronary artery disease. The pathophysiology and characteristics of cardiomyopathy associated with radiation therapy and anthracycline therapy are distinctive. We describe each type of cardiomyopathy, along with its risk factors. These distinctive cardiomyopathies require different screening tests. Appropriate screening of the entire cardiovascular system should be performed because radiation and chemotherapy affect the entire system. Prevention recommendations focus on cardiomyopathy and coronary artery disease.
Related Papers
- → Chemotherapy-induced cardiotoxicity in children(2017)84 cited
- → Genotyping the risk of anthracycline-induced cardiotoxicity(2007)79 cited
- [Cardiotoxicity of conservative treatment of solid tumors].(2012)
- Anthracycline-induced cardiotoxicity, a pathophysiology based approach for early detection and protective strategies(2012)